Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBPβ

Nature Medicine

Volumn 3, Issue 11, 1997, Pages 1233-1241

  Chinery, Rebecca ^a,b   Brockman, Jeffrey A ^b   Peeler, Mark O ^b   Shyr, Yu ^b,c   Beauchamp, R Daniel ^a,b,c   Coffey, Robert J ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BINDING PROTEIN; DOXORUBICIN; FLUOROURACIL; PROTEIN P21; PROTEIN P53; PYRROLIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION;

EID: 0030663670     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1197-1233     Document Type: Article

References (55)

1. Parker, S. L. et al. Cancer statistics. CA Cancer J. Clin. 46, 5-27 (1996).
2. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994)
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J. Clin. Oncol. 10, 896-903 (1992).
4. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
5. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
6. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 253, 49-53 (1991).
7. Levine, A., Momand, J. & Finlay, C.A. The p53 tumor suppressor gene. Nature 351, 453-456 (1991).
8. Boyle, P., Zaridze, D.G. & Smans, M. Descriptive epidemiology of colorectal cancer. Int. J. Cancer 36, 9-18 (1985).
9. Byers, T. & Perry, C. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu. Rev. Nutr. 12, 139-159 (1992).
10. Stone, W.L. & Papas, A.M. Tocopherols and the etiology of colon cancer. J. Natl. Cancer Inst. 89, 1006-1014 (1997).
11. Greenwald, P., Kelloff, G. J., Burch-Whitman, C. & Kramer, B. S. Chemoprevention. CA Cancer. J. Clin. 45, 31-49 (1995).
12. Turley, J.M. et al. Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: Role for transforming growth factor β. Cell. Growth Differ. 6, 655-663 (1995).
13. Tsai, J.C. et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J. Biol. Chem. 271, 3667-3670 (1996).
14. Church, S.L. et al. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. USA 90, 3313-3317 (1993).
15. Rautalahti, M. & Huttunen, J. Antioxidants and carcinogenesis. Ann. Med. 25, 435-441 (1993).
16. Irani, K. et al. Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. Science 275, 1649-1652 (1997).
17. Herrmann, R. Biochemical modulation of 5-fluorouracil. Cancer Treat. Rev. 17, 51-55 (1990).
18. Cummings, J., Anderson, L., Willmott, N. & Smyth, J.F. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer 27, 532-535 (1991).
19. Peters, G.J. et al. Thymidylate synthase and drug resistance. Eur. J. Cancer 31, 1299-1305 (1995).
20. Bendich, A. & Machlin, L.J. Safety of oral intake of vitamin E. Am. J. Clin Nutr. 48, 612-619 (1988).
21. Sunderman, F.W. Therapeutic properties of sodium diethyldithiocarbamate: Its role as an inhibitor in the progression of AIDS. Ann. Clin. Lab. Sci. 21, 70-81 (1991).
22. 1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995).
23. Gorospe, M., Wang, X., Guyton, K.Z. & Holbrook, N.J. Protective role of p21 (Waf1/Cip1) against prostaglandin A2-mediated apoptosis in human colorectal cancer cells. Mol. Cell. Biol. 16, 6654-6660 (1996).
24. Polyak, K., Waldman, T., He, T.C., Kinzler, K.W. & Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10, 1945-1952 (1996).
25. Wang, J. & Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273, 359-361 (1996).
26. Wu, G.S. & El-Deiry, W.S. Apoptotic death of tumor cells correlates with chemosensitivity of p53 or Bcl-2. Clin. Cancer Res. 2, 623-633 (1996).
27. WAF1/CIP1 deficient in PCNA interaction. Clin. Cancer Res. 2, 1221-1230 (1996).
28. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J. & Howley, P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
29. Kubbutat, M.H.C. & Vousden, K.H. Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies. Semin. Virol. 7, 295-304 (1996).
30. 1 arrest in human cancer cells. Cancer Res. 55, 5187-5190 (1995).
31. El-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
32. Landschulz, W.H., Johnson, P.F., Adahi, E.Y., Graves, B.J. & McKnight, S.L. Isolation of a recombinant copy of the gene encoding C/EBP gene. Genes Dev. 2, 786-800 (1988).
33. Akira, S. et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMSO J. 9, 1897-1906 (1990).
34. Poli, V., Mancini, P.P. & Cortese, R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell 63, 643-653 (1990).
35. Cao, Z., Umek, R.M. & McKnight, S.L. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 5, 1538-1552 (1991).
36. Williams, S.C., Cantwell, C.A. & Johnson, P.F. A family of C/EBP-related proteins capable of forming covalently linked leucine zippers dimers in vitro. Genes Dev. 5, 1553-1567 (1991).
37. Akira, S. & Kishimot, T. IL-6 and NF-IL6 in acute-phase response to viral infection. Immunol. Rev. 127, 25-50 (1992).
38. Timchenko, N.A., Wilde, M., Nakanishi, M., Smith, J.R. & Darlington, G.J. CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev. 10, 804-815 (1996).
39. Isshiki, H. et al. Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol. Cell. Biol. 10, 2757-2764 (1990).
40. Vasseur-Cognet, M. & Lane, M.D. Trans-acting factors involved in adipogenic differentiation. Curr. Opin. Gen. Dev. 3, 238-245 (1993).
41. Beg, A.A. & Baltimore, D. An essential role of NF-κB in preventing TNF - induced cell death. Science 274, 782-784 (1996).
42. Wang, C.Y., Mayo, M.W. & Baldwin, A.S. TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274, 784-787 (1996).
43. Van Antwerp, D.J., Martin, S.J., Kafri, T., Green, D.R. & Verma, I.M. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274, 787-789 (1996).
44. Grimm, S., Bauer-Manuel, K.A., Baeuerle, P.A. & Schulze, K.O. Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J. Cell. Biol. 134, 13-23 (1996).
45. Schreck, R., Grassmann, R., Fleckenstein B. &, Baeuerle P.A. Antioxidants selectively suppress activation of NF-kappaB by human T-cell leukemia virus type I Tax protein. J. Virol. 66, 6288-6298 (1992).
46. Traenckner, E.B. et al. Phosphorylation of human I kappaB-alpha on serines 32 and 36 controls I kappaB-alpha proteolysis and NF-kappaB activation in response to diverse stimuli. EMBO J. 14, 2876-2883 (1995).
47. Perkins, N.D. et al. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275, 523-527 (1997).
48. Harper, J.W., Hannon, G.J., Zhang, H., Casso, D. & Elledge, S.J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
49. Xiong, Y. et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704 (1993).
50. WAF1/CIP1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995).
51. Hunter, T. & Pines, J. Cyclins and cancer: Cyclin D and CDK inhibitors come of age. Cell 79, 573-582 (1994).
52. Lemarie, E., Musset, M., Charbonnier, C., Renoux, M. & Renoux, G. Clinical characterization of Imuthiol. Methods Exp. Clin. Pharmacol. 8, 51-54 (1986).
53. Reisinger, E. et al. Inhibition of AIDS progression by dithiocarb. Lancet 335, 679-682 (1990).
54. Danielson, P.E. et al. p1b15: A cDNA clone of the rat mRNA encoding cyclophilin. DNA 7, 261-267 (1988).
55. Kapiloff, M.S., Farkash, Y., Wegner, M. & Rosenfeld, M.G. Variable effects of phosphorylation of Pit-1 dictated by the DNA response elements. Science 253, 786-789 (1991).